Michael Nissen
Family · Raeford, NCNPI 1417077827
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 318 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 19.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,310 and has fallen 99.4% since, to $15 in 2025. Among family clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 318 payments — averaging $20.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$953
- Lilly USA, LLC$576
- Boehringer Ingelheim$575
- Merck$395
- Johnson & Johnson$342
- plus $2K from 25 others
What the payments were for
- Food & beverage$6,443100%
- Education$250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 34 | $1,279 |
| Novo Nordisk | 59 | $953 |
| Lilly USA, LLC | 33 | $576 |
| Boehringer Ingelheim | 23 | $575 |
| Merck | 22 | $395 |
| Johnson & Johnson | 9 | $342 |
| Amgen | 21 | $339 |
| GSK | 20 | $282 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $207 |
| Sanofi-aventis U.S. LLC | 10 | $184 |
| Bayer | 10 | $174 |
| Novartis | 9 | $157 |
| Exact Sciences | 6 | $138 |
| AbbVie | 7 | $129 |
| Ironwood Pharmaceuticals, Inc | 7 | $126 |
| Pfizer | 8 | $122 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $68 |
| Nestle Healthcare Nutrition Inc. | 3 | $56 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $54 |
| Abbott | 2 | $51 |
| Amarin Pharma, Inc. | 3 | $42 |
| E.r. Squibb & Sons, L.L.C. | 3 | $38 |
| Sunovion Pharmaceuticals Inc. | 2 | $30 |
| Biohaven Pharmaceuticals, Inc. | 2 | $29 |
| Hikma Pharmaceuticals USA | 2 | $25 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Edwards Lifesciences | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Eyevance Pharmaceuticals LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,468 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 38 | $31,166 |
| JardianceEmpagliflozin | 28 | $18,812 |
| XareltoRivaroxaban | 18 | $12,273 |
| Atorvastatin Calcium | 179 | $1,863 |
| Amlodipine-ValsartanAmlodipine Besylate/Valsartan | 12 | $1,139 |
| Omeprazole | 77 | $1,068 |
| Amlodipine Besylate | 143 | $877 |
| Losartan Potassium | 43 | $664 |
| Gabapentin | 32 | $483 |
| Pantoprazole Sodium | 32 | $468 |
| Alendronate Sodium | 34 | $455 |
| Lisinopril | 98 | $441 |
| Levothyroxine Sodium | 45 | $418 |
| Rosuvastatin Calcium | 39 | $409 |
| Potassium Chloride | 24 | $375 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $1,279 | $31,16638 claims |
| Boehringer IngelheimJardiance | $575 | $18,81228 claims |
| Johnson & JohnsonXarelto | $342 | $12,27318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.
Other family in Raeford
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
- Teresa DossWilmington$137K
- Debra ScottCharlotte$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.